Pfizer Announces Corporate Restructuring and Clinical Trial Adjustments
Pfizer has initiated a corporate restructuring and workforce reduction program while simultaneously adjusting its clinical trial pipeline.
Stocks · News reference
Pfizer Announces Positive Topline Results from Phase 3 MagnetisMM-32 Study of ELREXFIO
Pfizer reported that its Phase 3 MagnetisMM-32 trial met its primary endpoint of progression-free survival in patients with relapsed or refractory multiple myeloma.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight
The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.
Pfizer Divests Stake in ViiV Healthcare
Pfizer has exited its equity holding in the HIV-focused joint venture ViiV Healthcare, receiving $1.875 billion as part of a restructuring transaction.